Chronic antibody-mediated rejection,
Showing 26 - 50 of >10,000
Lung Transplant Recipient, Donor Specific Antibodies, Antibody Mediated Rejection Trial in France (bronchoscopy.)
Recruiting
- Lung Transplant Recipient
- +2 more
- bronchoscopy.
-
Le Plessis Robinson, France
- +4 more
Feb 11, 2022
Transplant Rejection Trial in Worldwide (BIVV020, Intravenous immunoglobulin (IVIg), Rituximab)
Recruiting
- Transplant Rejection
- BIVV020
- +6 more
-
Westmead, New South Wales, Australia
- +14 more
Aug 2, 2022
Incidence, Course and Outcome of ABMR in Kidney Transplantation
Not yet recruiting
- Antibody-mediated Rejection
- +2 more
- Kidney Transplantation
- +2 more
- (no location specified)
Nov 17, 2021
Kidney Transplantation, Antibody Mediated Rejection Trial in La Tronche (Sessions of conventional apheresis, Sessions of news
Unknown status
- Kidney Transplantation
- Antibody Mediated Rejection
- Sessions of conventional apheresis
- Sessions of news apheresis with double filtration
-
La Tronche, FranceGrenoble Alpes University Hospital
Mar 26, 2020
Decreased Immunologic Activity, Antibody-mediated Rejection Trial in Vienna (Combined apheresis)
Terminated
- Decreased Immunologic Activity
- Antibody-mediated Rejection
- Combined apheresis
-
Vienna, AustriaDivision of Medicine III, Dpt. of Nephrology and Dialysis, Medic
Aug 22, 2022
Antibody-mediated Rejection, NMO Spectrum Disorder, TTP Trial in Iowa City
Recruiting
- Antibody-mediated Rejection
- +3 more
-
Iowa City, IowaDeGowin blood Center
Oct 31, 2022
Kidney Transplant Trial in Rochester (Low dose adipose tissue derived mesenchymal stromal cells (A-MSC), High dose adipose
Recruiting
- Kidney Transplant
- Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)
- High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
-
Rochester, MinnesotaMayo Clinic
Jul 8, 2022
Graft Rejection Trial in Germany, United States (Placebo, C1 Esterase Inhibitor (Human))
Completed
- Graft Rejection
- Placebo
- C1 Esterase Inhibitor (Human)
-
Los Angeles, California
- +4 more
Jun 2, 2021
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder Trial in Wuhan (CT103A
Recruiting
- Autoimmune Diseases
- +5 more
- CT103A cells
- Cyclophosphamide and fludarabine
-
Wuhan, Hubei, ChinaTongji Hospital affiliated to Tongji Medical College of Huazhong
Dec 10, 2022
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction Trial in Los Angeles
Completed
- Antibody-mediated Rejection
- +4 more
-
Los Angeles, CaliforniaCedars Sinai Medical Center, Heart Institute
Apr 30, 2021
Adult Patients Treated in Study R5459-RT-1944 Who Receive A
Not yet recruiting
- Chronic Kidney Disease (CKD)
- Noninterventional
- (no location specified)
Nov 21, 2022
Lung Transplant Rejection, Antibody-mediated Rejection Trial in Saint Louis, Houston (Belatacept, Tacrolimus, ATG)
Active, not recruiting
- Lung Transplant Rejection
- Antibody-mediated Rejection
- Belatacept
- +5 more
-
Saint Louis, Missouri
- +1 more
Nov 2, 2021
Antibody-mediated Rejection Trial in Vienna, Berlin (Clazakizumab / Clazakizumab, Placebo / Clazakizumab)
Completed
- Antibody-mediated Rejection
- Clazakizumab / Clazakizumab
- Placebo / Clazakizumab
-
Vienna, Austria
- +1 more
Sep 6, 2020
Chronic Kidney Disease, Inflammation, Cardiovascular Risk Trial in Ehime (Ziltivekimab, Placebo (ziltivekimab))
Completed
- Chronic Kidney Disease
- +2 more
- Ziltivekimab
- Placebo (ziltivekimab)
-
Ehime, JapanNovo Nordisk Investigational Site
Oct 26, 2021
Quantitative Parameters of HLA-DQ Antibodies in Lung
Completed
- Lung Transplantation
- +2 more
-
Bordeaux, France
- +4 more
Apr 28, 2020
Kidney Transplantation Trial in Paris (Privigen (Human normal immunoglobulin G (IgG > 98 % purity)))
Completed
- Kidney Transplantation
- Privigen (Human normal immunoglobulin G (IgG > 98 % purity))
-
Paris, Ile De France, FranceService de Néphrologie et transplantation rénale - HU Saint-Loui
Mar 8, 2021
Kidney Transplant Rejection Trial in Aurora (Tacrolimus Extended Release Oral Tablet [Envarsus], Plasma Exchange and IVIG
Terminated
- Kidney Transplant Rejection
- Tacrolimus Extended Release Oral Tablet [Envarsus]
- Plasma Exchange and IVIG (Intravenous Immunoglobulin )
-
Aurora, ColoradoUniversity of Colorado Anschutz Medical Campus
Oct 23, 2020
Cell-based Assays for Antibody-mediated Transplant Rejection
Recruiting
- Antibody-Mediated Graft Rejection
- Alloantigen-specific B-cells
-
Buffalo, New York
- +1 more
Sep 21, 2020
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute
Recruiting
- Acute Rejection of Renal Transplant
- Graft Failure
- Donor-derived cell-free DNA
-
Loma Linda, CaliforniaLoma Linda University Health
Jul 19, 2022
Interventional Trial in Ljubljana (MSC transplantation)
Terminated
- Interventional
- MSC transplantation
-
Ljubljana, SloveniaUniversity Medical Centre Ljubljana
Jul 24, 2019
s for Acute Antibody-Mediated Rejection of the Kidney Transplant
Not yet recruiting
- Transplant; Complication, Rejection
- (no location specified)
Jul 29, 2020
Kidney Injury, Kidney Failure, Kidney Failure, Chronic Trial in Washington (AlloSure, PAXGene)
Suspended
- Kidney Injury
- +9 more
- AlloSure
- PAXGene
-
Washington, District of ColumbiaGeorge Washington University
Feb 16, 2023
Development of Antibodies Against Transplant Kidney After
Completed
- Acute Infection
- Kidney Failure
- Level of antibodies
-
Ostrava, Moravian-Silesian Region, CzechiaUniversity Hospital Ostrava
Sep 8, 2023
Kidney Rejection Transplant Trial in Poznan (Assessment of the drug concentration in the blood)
Active, not recruiting
- Kidney Rejection Transplant
- Assessment of the drug concentration in the blood
-
Poznan, PolandUniversity Clinical Hospital in Poznan of the Poznan University
Jan 19, 2023
Kidney; Complications, Allograft, Transplantation Infection Trial in Loma Linda (Immunosuppressive Agents)
Active, not recruiting
- Kidney; Complications, Allograft
- Transplantation Infection
- Immunosuppressive Agents
-
Loma Linda, CaliforniaLoma Linda University Medical Center, Transplantation Institute
Apr 28, 2022